Pliant Therapeutics (PLRX) Capital Expenditures (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Capital Expenditures of -$323000.0 for Q1 2026, down 223.28% year-over-year from $262000.0 in Q1 2025, and up 22.54% quarter-over-quarter from -$417000.0 in Q4 2025.
Pliant Therapeutics (PLRX) Capital Expenditures (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Capital Expenditures for 8 consecutive years, with -$323000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 223.28% year-over-year to -$323000.0; the TTM figure through Mar 2026 stood at -$628000.0 (down 115.28% YoY), while the FY2025 annual figure was -$43000.0, down 101.12% from the prior year.
- Capital Expenditures rose to -$323000.0 in Q1 2026 per PLRX's latest filing, from -$417000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $3.7 million in Q4 2024 and bottomed at -$2.6 million in Q3 2024.
- Historically, Capital Expenditures has averaged $410866.7 across 5 years, with a median of $254000.0 in 2022.
- On a YoY basis, Capital Expenditures climbed as much as 5991.8% in 2024 and fell as far as 2877.66% in 2024.
- Pliant Therapeutics' Capital Expenditures stood at $1.7 million in 2022, then plunged by 96.47% to $61000.0 in 2023, then surged by 5991.8% to $3.7 million in 2024, then slumped by 111.22% to -$417000.0 in 2025, then advanced by 22.54% to -$323000.0 in 2026.
- Business Quant data shows PLRX's Capital Expenditures at -$323000.0 in Q1 2026, -$417000.0 in Q4 2025, and $262000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.54 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.41 Bn | 54.27 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 251.02 Mn |
| 10 | Pliant Therapeutics | 71.52 Mn | 71.52 Mn | - | 192,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 192,000.00 |
| Jun 30, 2026 | 192,000.00 |
| Mar 31, 2026 | -323,000.00 |
| Mar 31, 2026 | -323,000.00 |
| Dec 31, 2025 | -417,000.00 |
| Dec 31, 2025 | -417,000.00 |
| Sep 30, 2025 | 262,000.00 |
| Sep 30, 2025 | 262,000.00 |
| Jun 30, 2025 | -150,000.00 |
| Jun 30, 2025 | -150,000.00 |
| Mar 31, 2025 | 262,000.00 |
| Mar 31, 2025 | 262,000.00 |
| Dec 31, 2024 | 3.72 Mn |
| Dec 31, 2024 | 3.72 Mn |
| Sep 30, 2024 | -2.61 Mn |
| Sep 30, 2024 | -2.61 Mn |
| Jun 30, 2024 | 2.74 Mn |
| Jun 30, 2024 | 2.74 Mn |
| Dec 31, 2023 | 61,000.00 |
| Dec 31, 2023 | 61,000.00 |